newsfilter
← Latest News
PR Newswire·

Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients

Tetra and Cellvera to jointly develop an orally administered treatment, ARDS-003, in combination with the proven broad-spectrum antiviral, Qifenda 400MG (Favipiravir) Companies will jointly develop a combination therapeutic candidate for rapid clearanc